Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Satoshi, Yoda"'
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Random forest regression was applied to optimize the melt-blending process of polyphenylene sulfide (PPS) with poly(ethylene-glycidyl methacrylate-methyl acrylate) (E-GMA-MA) elastomer to improve the Charpy impact strength. A training datase
Externí odkaz:
https://doaj.org/article/aa32a63b6bc74d2e8c0bb61df33694d6
Autor:
Farideh Davoudi, Samar Ghorbanpoor, Satoshi Yoda, Xiao Pan, Giovanna Stein Crowther, Xunqin Yin, Ellen Murchie, Aaron N. Hata, Henning Willers, Cyril H. Benes
Publikováno v:
STAR Protocols, Vol 2, Iss 2, Pp 100391- (2021)
Summary: Two-dimensional (2D) culture of tumor cells fails to recapitulate some important aspects of cellular organization seen in in vivo experiments. In addition, cell cultures traditionally use non-physiological concentration of nutrients. Here, w
Externí odkaz:
https://doaj.org/article/71211847c6f34c619a6501fb7eae1612
Publikováno v:
Frontiers in Materials, Vol 8 (2021)
A new flexible thermal insulation sheet, a composite of silica aerogel with polypropylene (PP) foam, has been developed. Even though a large volume ratio of silica aerogel (97%) was included, the composite showed high flexibility. Thermal conductivit
Externí odkaz:
https://doaj.org/article/e9b05c8140fc4c85ab56997f6999facf
Autor:
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical mod
Externí odkaz:
https://doaj.org/article/1fb146a2c258459e81f631757ffb5a98
Publikováno v:
Surface and Interface Analysis. 55:256-262
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
NVL-520 Modeling, Properties, Biochemical Activity, Cellular Activity, and In Vivo Activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179b478fa795d20f06c52f43443d2a80
https://doi.org/10.1158/2159-8290.22542255
https://doi.org/10.1158/2159-8290.22542255
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04fc95b4f0ef39c29165338ddd307aa5
https://doi.org/10.1158/2159-8290.c.6549846
https://doi.org/10.1158/2159-8290.c.6549846
Autor:
Alice T. Shaw, Jeffrey A. Engelman, Mari Mino-Kenudson, A. John Iafrate, Cyril H. Benes, Lecia V. Sequist, Jochen Lennerz, Rebecca S. Heist, Dora Dias-Santagata, Gad Getz, Colleen Keyes, Colleen Channick, Subba Digumarthy, Ashok Muniappan, Long P. Le, Lauren L. Ritterhouse, Jennifer Logan, Tiffany Huynh, Elizabeth Lockerman, Richard H. DiCecca, Dana Lee, Melissa Parks, Emily Chin, Manrose Singh, Katherine Schultz, Shirish Gadgeel, Ibiayi Dagogo-Jack, Ryohei Katayama, Ignaty Leshchiner, Luc Friboulet, Satoshi Yoda, Leila Dardaei, Justin F. Gainor
Supplementary Table S1. ALK inhibitors in clinical development. Supplementary Table S2. Summary of clinical characteristics of ALK-positive patients undergoing biopsies at the time of ALK inhibitor resistance. Supplementary Table S3. Paired, post-cri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f44b92d5a824882ff78594553ca374
https://doi.org/10.1158/2159-8290.22531515.v1
https://doi.org/10.1158/2159-8290.22531515.v1
Autor:
Alice T. Shaw, Aaron N. Hata, Ted W. Johnson, Jeffrey A. Engelman, Mari Mino-Kenudson, Jochen K. Lennerz, Cyril H. Benes, A. John Iafrate, Rebecca S. Heist, Daria Timonina, Krystina E. Kattermann, Amanda K. Riley, Lorin A. Ferris, Justin F. Gainor, Harper Hubbeling, Sergei Timofeevski, Ibiayi Dagogo-Jack, Kylie Prutisto-Chang, Leila Dardaei, Adam Langenbucher, Luc Friboulet, Benjamin J. Burke, Michael S. Lawrence, Jessica J. Lin, Satoshi Yoda
suppl tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::695e64cddb17425642cdd97e3a2d9049
https://doi.org/10.1158/2159-8290.22532569
https://doi.org/10.1158/2159-8290.22532569
Autor:
Tomoko Betsuyaku, Katsuhiko Naoki, Ryosuke Satomi, Satoshi Yoda, Takashi Sato, Shinnosuke Ikemura, Keiko Ohgino, Kota Ishioka, Daisuke Arai, Junko Hamamoto, Sohei Nakayama, Hiroyuki Yasuda, Kenzo Soejima, Hideki Terai
Supplementary Figure S6 - PDF file 180K, A, B. Viability curves of PC9 GR cells (A) and PC9 gr1 cells (B) transfected with siRNA against FGFR1 (FGFR1 siRNA #1), FGFR3, or with the negative control mix at indicated concentrations of gefitinib. Represe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::526b61b401a7c54b7af6981c62fbcea2
https://doi.org/10.1158/1541-7786.22509937.v1
https://doi.org/10.1158/1541-7786.22509937.v1